The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative assessment of different radiological criteria to identify paradoxical hyperprogression (HPD) to IO drugs.
 
Ana Luiza Gomes de Morais
No Relationships to Disclose
 
Jose M Cardenas
No Relationships to Disclose
 
Maria Jose de Miguel Luken
Honoraria - Janssen Oncology; MSD Oncology
 
Valentina Boni
Honoraria - IDEAYA Biosciences; Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - START
 
Irene Moreno
No Relationships to Disclose
 
Gerileto Ao
No Relationships to Disclose
 
Run Han Liu
No Relationships to Disclose
 
Fernando Bergaz de Hoyos
No Relationships to Disclose
 
Antonio Cubillo
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Investigational Therapeutics in Oncological Sciences